Introduction
============

Talniflumate, 3-pyridinecarboxylic acid 2-{\[(3-trifluoromethyl) phenyl\]amino}-1,3-dihydro-3-oxo-1-soenzofuranyl ester, is a phthalidyl ester of niflumic acid and is currently used to treat osteoarthritis and rheumatoid arthritis.\[[@B1][@B2]\] Niflumic acid shows rapid absorption followed by extensive metabolism, involving hydroxylation or glucuronidation.\[[@B3]\] However, the occurrence of side effects such as gastrointestinal irritation has been reported both in experimental animals and in clinical use. In order to lower ulcergenic activity, talniflumate was synthesized by esterification of the carboxyl group of niflumic acid.\[[@B4]\] Many genetic and non-genetic factors such as age, sex, life style, organ function, concomitant therapy, and the nature of the disease influence the effects of medications.\[[@B5]\] Following the Human Genome Project, it is understood that genetic factors can influence the response of an individual to a drug.\[[@B6]\] In clinical pharmacogenomics, drug-metabolizing enzymes.\[[@B7][@B8]\] drug transporters.\[[@B9]\] and other genes have been known to influence the individual differences in drug response.

Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation, and are proven to significantly affect drug absorption, distribution, biotransformation, and excretion.\[[@B10]\] Our previous studies showed that the pharmacokinetics (PK) of simvastatin and pioglitazone are affected by the genotype of each individual.\[[@B11][@B12]\]

The purpose of this study was to screen possible candidate genes affecting the PK of talniflumate. A total of 23 male Korean volunteers were recruited from two bioequivalence studies after approval by the Institutional Review Board (IRB) of Kyung Hee University Hospital. In this study, DNA from each subject was analyzed using Illumina Human610Quad v1.0 DNA Analysis BeadChip. Linear regression analysis was performed for significant SNPs affecting PK parameters, such as maximum measured plasma concentration (*C*~max~), time of the maximum measured plasma concentration (*T*~max~), and area under the plasma concentration-time curve from zero to infinity (AUC~*inf*~). For clinical pharmacological purposes, further analysis was performed on significant SNPs encoding phase I and II drug metabolizing enzymes to examine their effect on the PK of talniflumate.

Methods
=======

Subjects
--------

Volunteers were healthy Korean males who participated in two talniflumate bioequivalence tests at Kyung Hee Clinical Medical Research Institute of Kyung Hee University Hospital. The clinical protocol was approved by the IRB of Kyung Hee University Hospital and volunteers were recruited by direct call. Twenty-three out of 60 subjects from these previous tests participated in this pharmacogenetics study after providing written informed consent. The demographic characteristics of the volunteers are summarized in [Table 1](#T1){ref-type="table"}. Subjects ranged in age from 20 to 35 years (26 ± 3.6 years), in weight from 57.0 to 90.0 kg (68.7 ± 8.3 kg), and in height from 160.0 to 184.0 cm (173.3 ± 4.8 cm) ([Table 1](#T1){ref-type="table"}).

Previous bioequivalence studies
-------------------------------

Previous studies were based on two talniflumate bioequivalence tests. Each bioequivalence study of two 370 mg talniflumate formulations (reference drug, Somalgen tablet 370 mg, Kunhwa Co., Ltd.) was conducted in healthy male Korean volunteers after a single dose administration in a randomized cross-over study with a washout period of at least one week. The subjects were hospitalized (Kyung Hee University Hospital, Seoul, Korea) and fasted overnight (10 h) and for 4 h after each drug administration. The doses were administered at 8.00 a.m. of each dosing day along with 240 ml of tap water. No food was allowed until 4 h after dose administration. Approximately 7 ml of blood for talniflumate and active metabolite assays were drawn into heparinized tubes through indwelling cannula before (0 h) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 15 h after dosing. Blood samples were centrifuged at 3,000 rpm for 10 min; plasma was separated and kept frozen at −70℃ until assayed. Plasma was analyzed for talniflumate concentration using a validated high-performance liquid chromatography method.

Pharmacokinetics analysis
-------------------------

PK parameters (*C*~max~, *T*~max~, *AUC*~t~ and *AUC*~inf~) were calculated by noncompartmental models in WinNonlin v5.2 ([Table 1](#T1){ref-type="table"}).

DNA extraction
--------------

DNA extraction was performed as previously described.\[[@B11]\] From May to August 2008, blood samples were obtained from 23 participants. After obtaining informed consent, approximately 10 ml of whole blood was collected from each participant. Blood samples were drawn into sterile tubes containing ethylenediaminetetraacetic acid (EDTA) and stored at −70℃ until the isolation of genomic DNA by a standard phenol chloroform extraction method.

Genotyping
----------

SNPs of 23 healthy male volunteers were analyzed by Standard Illumina procedures using Illumina BeadStation 500G (Illumina Human610Quad v1.0 DNA Analysis BeadChip) as previously described.\[[@B11][@B12]\] Intensity files (\*.idat) were processed by BeadStudio GT module 3.3.4 with default analysis settings. Each SNP was analyzed independently to cluster and identify genotypes. Genotype calls were generated by comparing experimental data with those in the supplied cluster file (\*.egt). The SNP set was filtered on the basis of genotype call rates (≥ 95%), and minor allele frequency (MAF ≥ 0.05).

Statistical analysis & data analysis
------------------------------------

Statistical analysis was performed as previously described.\[[@B11][@B12]\] Hardy Weinberg equilibrium (HWE) was calculated for individual SNPs using an exact test. All of the SNPs reported in this manuscript have HWE *P*-values \> 0.001. To calculate the degree (Beta), 95% confidence intervals (CI) and *P*-value while controlling for age, height and weight as covariants in a linear regression analysis with significant SNPs on individual PK parameters of talniflumate, unadjusted genotypic association with additive, dominant and recessive models were tested by calculating the Beta and *P*-value using PLINK version 1.06 (Shaun Purcell, USA). When the additive model was used, each genotype was independently coded as 0, 1, or 2 and analyzed. In the dominant model, a homozygote major allele and another two genotypes were coded as 0 and 1 and analyzed. In the recessive model, a homozygote minor allele and another two genotypes were coded a 0 and 1 and analyzed. After filtering, SNPs were analyzed on chromosome 1 through chromosome 22 for each group.

Significant SNPs were identified from each PK parameter (*C*~max~, *T*~max~ and *AUC*~inf~). These included SNPs of phase I and II drug metabolizing enzymes, which were selected to further analyze their effect on the PK parameters (two SNPs in *C*~max~, two SNPs in *T*~max~ and two SNPs in *AUC*~inf~).

Results
=======

Pharmacokinetics analysis
-------------------------

The PK parameters of talniflumate are shown in [Table 1](#T1){ref-type="table"}. *C*~max~ is 230.9 ± 113.5 µg/L, *T*~max~ is 3.0 ± 1.2 h, AUCt is 1058.6 ± 557.1 µg·h/L, and *AUC*~inf~ is 1100 ± 621.9 µg/L. These data were used for linear regression analysis.

SNP analysis
------------

Linear regression analysis was performed on the PK parameters of talniflumate (*C*~max~, *T*~max~, and *AUC*~inf~). In this analysis, 25,361 significant SNPs in the *C*~max~ group, 24,067 significant SNPs in the *T*~max~ group, and 23,604 significant SNPs in the *AUC*~inf~ group showed significant associations (P\<0.05). Among those significant SNPs, 1,498 SNPs from the Cmax group, 65 SNPs from the T~max~ group, and 1,491 SNPs from the AUC~inf~ group showed highly significant associations with each parameter ([Table 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, P\<0.0001). All data were adjusted for age, height, and weight. For clinical pharmacological purposes, significant SNPs encoding phase I and II drug metabolizing enzymes were selected for further analysis.

We selected two SNPs for further analysis from the *C*~max~ group (rs11165069 from ABCA4; rs17847036 from CYP2C9 [Table 2](#T2){ref-type="table"}), the *T*~max~ group (rs3787555 from CYP24A1; rs2275034 from ABCA4, [Table 3](#T3){ref-type="table"}), and the *AUC*~inf~ group (rs11165069 from ABCA4; rs12461006 from SLC1A6, [Table 4](#T4){ref-type="table"}).

ABCA4 (rs11165069, P = 0.000001 in *C*~max~ group; rs2275034, P = 0.000587 in the *T*~max~ group; rs11165069, P = 0.00002 in *AUC*~inf~ group) showed statistically significant changes by genotype ([Fig. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, and [3](#F3){ref-type="fig"} and [Table 5](#T5){ref-type="table"}). ABCA4 gene polymorphisms affect talniflumate PK parameters. These data show that genetic polymorphism of ABCA4 has a profound effect on the PK of talniflumate.

In the *C*~max~ group, CYP2C9 rs17847036 showed statistically significant changes according to genotype; the AG genotype exhibited a greater *C*~max~ value ([Fig. 1](#F1){ref-type="fig"} and [Table 5](#T5){ref-type="table"}).

In the *T*~max~ group, CYP24A1 rs37875551 with an AA genotype showed more than 2-fold increase in *T*~max~ than the CC genotype. ABCA4 rs2275034, with a CC genotype showed a 2-fold increase in *T*~max~ compared to the TT genotype ([Fig. 2](#F2){ref-type="fig"} and [Table 5](#T5){ref-type="table"}).

In the *AUC*~inf~ group, ABCA4 rs11165069 with a TC genotype showed a greater than 4-fold increase in *AUC*~inf~ than the CC genotype. SLC1A6 rs12461006 with an AG genotype showed a 3-fold increase in *AUC*~inf~ group compared to the GG genotype ([Fig. 3](#F3){ref-type="fig"} and [Table 5](#T5){ref-type="table"}).

Discussion
==========

Many factors affect talniflumate blood concentration, such as diet, age, liver function and disease condition. The genes involved in the process of drug absorption, distribution, metabolism and excretion may affect the PK of talniflumate \[[@B10][@B13][@B14]\] but the effect of pharmacogenetics factors has yet to be investigated. In this study, we performed whole genome association studies and regression analysis to investigate the genetic factors influencing the PK of talniflumate.

Regression analysis of significant SNPs and SNPs of candidate genes revealed several SNPs which significantly affect the PK of talniflumate. Interestingly, although SNPs of ABCA4 have low frequency, their effect was significant, resulting in increases in *C*~max~, *T*~max~ and *AUC*~inf~. Although these results were only obtained via screening studies, they are the first data concerning the influence of genes, including those responsible for metabolizing enzymes and transporters, on the PK of talniflumate.

We identified the significant association of SNP rs11165069 (P=0.000001) ([Fig. 1A](#F1){ref-type="fig"}) in intron 24 of the transporter gene ABCA4 with the *C*~max~ and *AUC*~inf~ of talniflumate. In our study, ABCA4 (rs1165069) with a TC increased the absorption of talniflumate by approximately four times compared to the CC genotype. Therefore, the TC genotype resulted in greater *C*~max~ (0.000001) and *AUC*~inf~ (P=0.00002) values. However, because of the low frequency of the TC genotype of ABCA4 rs11165069, further analysis is required. Furthermore, subjects in the *T*~max~ group with the minor C allele of the intron 37 SNP rs2275034 (P=0.00058) ([Fig. 2B](#F2){ref-type="fig"}) of ABCA4 showed a more than 2-fold delayed *T*~max~. From the result, it can be assumed that ABCA4 can affect the absorption of talniflumate and it is possible that the PK parameters can vary according to genotype.

Subjects with the minor A allele of the synonymous exon 2 SNP rs17847036 (P=0.000001) of the phase I enzyme gene CYP2C9 showed an increase in *C*~max~ ([Fig. 1B](#F1){ref-type="fig"}). It is well understood that CYP2C9 influences the metabolism of drug types \[[@B15]\] and these results indicate that the genotype of CYP2C9 could influence talniflumate plasma concentration.

Other genes, such as CYP24A1 (rs3787555) and SLC1A6 (rs12461006), showed significant associations with the PK of talniflumate, influencing *T*~max~ and *AUC*~inf~, respectively.

To the best of our knowledge, this is the first whole genome association study regarding the PK of talniflumate. However, the limitations of this study must be acknowledged. As this was a screening study, we performed only univariate analysis between genotypes and PK parameters. Therefore, further confirmative study on the PK of talniflumate with subgroup analysis according to genotypes is required. In conclusion, this study is useful in explaining why the PK of talniflumate may vary depending on the individual. As several additional drugs and enzymes may also influence talniflumate metabolism, we propose that genetic differences are major contributing factors in the PK of this drug.
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###### Demographic characteristics and reference talniflumate pharmacokinetic parameters of volunteers

![](tcp-25-166-i001)

  NO.        Age      Weight/kg   Height/cm   AUC~t~         AUC~inf~       C~max~        T~max~
  ---------- -------- ----------- ----------- -------------- -------------- ------------- ---------
  T1         25       66          180         906.13         999.72         159.44        6.0
  T2         26       90          184         622.32         622.32         123.95        4.0
  T3         26       69          175         779.54         779.54         145.57        4.0
  T4         28       75          171         2347.19        2443.90        437.40        3.0
  T5         26       64          168         1517.40        1593.58        250.04        2.5
  T6         25       61          171         517.70         583.46         113.53        2.0
  T7         28       66          160         472.36         472.36         137.56        1.5
  T8         20       57          171         1062.67        1143.30        239.89        4.0
  T9         24       58          174         1343.76        1397.23        349.84        2.0
  T10        24       68          173         1478.44        1589.52        218.99        6.0
  T11        22       72          174         1984.33        2102.38        357.11        4.0
  T12        30       68          170         1120.51        1201.74        257.67        3.0
  T13        24       85          176         1493.98        1571.46        394.48        4.0
  T14        22       62          170         836.85         882.83         164.70        3.0
  T15        22       71          177         1087.64        1087.64        178.06        3.0
  T16        30       66          175         458.10         517.74         87.99         3.0
  T17        35       80          176         600.89         152.32         152.32        2.5
  T18        27       73          178         628.44         628.44         193.06        1.5
  T19        34       70          168         1798.92        1901.22        489.93        1.5
  T20        26       68          174         501.71         501.71         145.15        2.5
  T21        24       61          172         447.39         545.75         235.83        2.5
  T22        25       58          173         596.64         596.64         125.06        2.0
  T23        25       73          177         1743.96        2007.03        355.20        2.5
  Mean±S.D   26±3.6   68.7±8.3    173.3±4.8   1058.6±557.1   1100.9±621.9   230.9±113.5   3.0±1.2

Abbreviations: C~max~, maximum measured plasma concentration; T~max~, time of the maximum measured plasma concentration; AUC~t~, area under the plasma concentration-time curve from time zero to time of last measurable concentration; AUC~inf~, area under the plasma concentration-time curve from zero to infinity; SD, standard deviation.

###### Highly significant SNPs identified in *C*~max~ group following regression analysis (P\<0.0001)

![](tcp-25-166-i002)

  Name         Chr   Gene       Location     g1   n1   m1       s1       g2   n2   m2       s2      P VALUE
  ------------ ----- ---------- ------------ ---- ---- -------- -------- ---- ---- -------- ------- ----------
  rs11165069   1     ABCA4      intron       CC   22   175.40   95.28    TC   1    831.52           0.000001
  rs7637682    3     SLC9A10    intron       AA   22   175.40   95.28    AG   1    831.52           0.000001
  rs4234409    3     SLC9A10    intron       AA   22   175.40   95.28    AC   1    831.52           0.000001
  rs4434123    3     SLC9A10    missense     AA   22   175.40   95.28    AG   1    831.52           0.000001
  rs17446282   3     SLC9A10    intron       AA   22   175.40   95.28    AG   1    831.52           0.000001
  rs2291550    12    ABCC9      synonymous   CC   22   175.40   95.28    TC   1    831.52           0.000001
  rs1051640    17    ABCC3      synonymous   AA   22   175.40   95.28    AG   1    831.52           0.000001
  rs757220     19    SLC25A42   intron       CC   22   175.40   95.28    TC   1    831.52           0.000001
  rs12150890   19    SLC7A9     synonymous   AA   22   175.40   95.28    AG   1    831.52           0.000001
  rs17724104   20    SLC9A8     intron       AA   22   175.40   95.28    AG   1    831.52           0.000001
  rs6781844    3     SLC9A10    missense     TG   1    831.52            TT   22   175.40   95.28   0.000001
  rs9855755    3     SLC9A10    intron       AG   1    831.52            GG   22   175.40   95.28   0.000001
  rs4646196    5     SLC22A4    intron       AG   1    831.52            GG   22   175.40   95.28   0.000001
  rs17847036   10    CYP2C9     synonymous   AG   1    831.52            GG   22   175.40   95.28   0.000001
  rs7248399    19    SLC25A42   intron       AG   1    831.52            GG   22   175.40   95.28   0.000001
  rs10417974   19    SLC25A42   3UTR         TC   1    831.52            TT   22   175.40   95.28   0.000001
  rs215096     16    ABCC1      intron       TC   3    527.07   264.40   TT   20   155.45   73.41   0.000015

Abbreviations: Chr, chromosome; N, number; g1, genotype 1; n1, number 1; s1, standard deviation 1; g2, genotype 2; n2, number 2; s2, standard deviation 2. ^\*^Table only shows several significant SNPs from a total of 1498 highly significant SNPs.

###### Highly significant SNPs identified in *T*~max~ group following regression analysis (P\<0.0001)
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  Name         chr   Gene        Location    g1   n1   m1     s1     g2   n2   m2     s2     g3   n3   m3     s3     P VALUE
  ------------ ----- ----------- ----------- ---- ---- ------ ------ ---- ---- ------ ------ ---- ---- ------ ------ ---------
  rs2072219    7     DNAH11      intron      AC   4    6.00   0.00   CC   19   2.84   0.94                           0.00000
  rs2084789    16    A2BP1       intron      AA   3    6.00   0.00   AG   2    5.00   1.41   GG   18   2.78   0.93   0.00000
  rs8008333    14    RAD51L1     intron      AA   18   2.78   0.93   AG   5    5.60   0.89                           0.00001
  rs4370152    4     LOC729112   intron      AA   13   2.46   0.85   AG   8    4.25   1.16   GG   2    6.00   0.00   0.00001
  rs770297     5     CDH18       3flanking   CC   2    6.00   0.00   TC   3    5.33   1.15   TT   18   2.78   0.93   0.00001
  rs10899786   10    RASGEF1A    intron      AA   7    5.00   1.29   AG   10   3.10   0.91   GG   6    2.00   0.45   0.00001
  rs2503853    10    RASGEF1A    intron      AA   7    5.00   1.29   AG   11   3.05   0.88   GG   5    1.90   0.42   0.00001
  rs3781832    11    SORL1       intron      GG   8    2.13   0.64   TG   10   3.50   1.15   TT   5    5.20   1.10   0.00002
  rs2452600    4     PDLIM5      missense    CC   6    2.08   0.38   TC   14   3.39   1.16   TT   3    6.00   0.00   0.00002
  rs7794797    7     CACNA2D1    intron      AA   11   4.55   1.21   AG   12   2.33   0.75                           0.00003
  rs6534295    4     LOC729112   intron      CC   10   2.25   0.79   TC   10   3.95   1.21   TT   3    5.33   1.15   0.00004
  rs1158024    4     LOC729112   intron      CC   3    5.33   1.15   TC   10   3.95   1.21   TT   10   2.25   0.79   0.00004
  rs12646248   4     LOC729112   intron      AA   10   2.25   0.79   AG   10   3.95   1.21   GG   3    5.33   1.15   0.00004
  rs13119523   4     LOC729112   intron      CC   10   2.25   0.79   TC   10   3.95   1.21   TT   3    5.33   1.15   0.00004
  rs12403933   1     C1orf125    intron      AA   13   2.54   0.85   AG   8    4.13   1.36   GG   2    6.00   0.00   0.00004
  rs3781834    11    SORL1       intron      AA   9    2.17   0.61   AG   11   3.86   1.27   GG   3    5.33   1.15   0.00004
  rs17125523   11    SORL1       intron      AA   9    2.17   0.61   AG   11   3.86   1.27   GG   3    5.33   1.15   0.00004
  rs12287339   11    SORL1       intron      CC   3    5.33   1.15   TC   11   3.86   1.27   TT   9    2.17   0.61   0.00004
  rs722074     16    XYLT1       intron      CC   2    6.00   0.00   TC   10   3.95   1.30   TT   11   2.41   0.80   0.00005
  rs6848730    4     MIST        intron      GG   2    6.00   0.00   TG   5    4.50   1.50   TT   16   2.72   0.93   0.00005
  rs187985     7     IGF2BP3     intron      CC   1    6.00          TC   6    4.83   1.33   TT   16   2.69   0.93   0.00006
  rs7728604    5     SLIT3       intron      CC   12   2.54   0.89   TC   7    3.64   1.31   TT   4    5.50   1.00   0.00007
  rs532841     8     DLC1        missense    CC   5    5.20   1.10   TC   12   3.29   1.16   TT   6    2.08   0.74   0.00008
  rs2136638    2     CDKL4       intron      CC   14   2.57   0.83   TC   8    4.50   1.41   TT   1    6.00          0.00008
  rs2302677    16    RPGRIP1L    missense    CC   18   2.83   0.97   TC   5    5.40   1.34                           0.00009
  rs9934800    16    RPGRIP1L    intron      TC   5    5.40   1.34   TT   18   2.83   0.97                           0.00009

Abbreviations: Chr, chromosome; N, number; g1, genotype 1; n1, number 1; s1, standard deviation 1; g2, genotype 2; n2, number 2; s2, standard deviation 2; g3, genotype 3; n3, number 3; s3; standard deviation. 3 ^\*^Table only shows several SNPs from a total of 65 highly significant SNPs.

###### Highly significant SNPs identified in *AUC*~inf~ group following regression analysis (P\<0.0001)
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  Name         chr   Gene       Location     g1   n1   m1        s1        g2   n2   m2        s2       P VALUE
  ------------ ----- ---------- ------------ ---- ---- --------- --------- ---- ---- --------- -------- ---------
  rs11165069   1     ABCA4      intron       CC   22   908.30    573.63    TC   1    4073.42            0.00002
  rs1051640    17    ABCC3      synonymous   AA   22   908.30    573.63    AG   1    4073.42            0.00002
  rs2291550    12    ABCC9      synonymous   CC   22   908.30    573.63    TC   1    4073.42            0.00002
  rs17847036   10    CYP2C9     synonymous   AG   1    4073.42             GG   22   908.30    573.63   0.00002
  rs12461006   19    SLC1A6     intron       AG   2    3049.93   1447.43   GG   21   855.06    529.17   0.00008
  rs4646196    5     SLC22A4    intron       AG   1    4073.42             GG   22   908.30    573.63   0.00002
  rs757220     19    SLC25A42   intron       CC   22   908.30    573.63    TC   1    4073.42            0.00002
  rs7248399    19    SLC25A42   intron       AG   1    4073.42             GG   22   908.30    573.63   0.00002
  rs10417974   19    SLC25A42   3UTR         TC   1    4073.42             TT   22   908.30    573.63   0.00002
  rs4980343    15    SLC28A1    intron       AG   1    4073.42             GG   22   908.30    573.63   0.00002
  rs12150890   19    SLC7A9     synonymous   AA   22   908.30    573.63    AG   1    4073.42            0.00002
  rs7637682    3     SLC9A10    intron       AA   22   908.30    573.63    AG   1    4073.42            0.00002
  rs4234409    3     SLC9A10    intron       AA   22   908.30    573.63    AC   1    4073.42            0.00002
  rs4434123    3     SLC9A10    missense     AA   22   908.30    573.63    AG   1    4073.42            0.00002
  rs17446282   3     SLC9A10    intron       AA   22   908.30    573.63    AG   1    4073.42            0.00002
  rs6781844    3     SLC9A10    missense     TG   1    4073.42             TT   22   908.30    573.63   0.00002
  rs9855755    3     SLC9A10    intron       AG   1    4073.42             GG   22   908.30    573.63   0.00002
  rs17724104   20    SLC9A8     intron       AA   22   908.30    573.63    AG   1    4073.42            0.00002

Abbreviations: Chr, chromosome; N, number, g1, genotype 1, n1, number 1; s1, standard deviation 1; g2, genotype 2; n2, number 2; s2, standard deviation 2 ^\*^Table only shows several SNPs from a total of 1498 highly significant SNPs.

###### Summary of regression Analysis
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  -------------------------------------- ------------------------------------ ------------------------------------------- -- --------------------- ----------- ----------- ------------------------- -- ------- ----------- -----------
  A. Results of *C*~max~ group (ng/ml)   B. Results of *T*~max~ group (Hhr)   C. Results of *AUC*~inf~ group (hr·ng/ml)                                                                                                     
                                         **ABCA4 / rs1165069**                                                               **CYP24A1**                                   **ABCA4 / rs1165069**                            
                                         CC (n=22)                            TC (n=1)                                                             AA (n=13)   AC (n=6)    CC (n=4)                             CC (n=22)   TC (n=1)
  mean                                   175.4                                775.532                                        mean                  4.25        2.73        1.8                          mean    908.3       4073.42
  stdev                                  95.28                                                                               stdev                 1.23        0.78        0.89                         stdev   573.63      
                                         **CYP2C9 / rs17847036**                                                             **GSTZ1/rs2270422**                           **SCL1A6 / rs12461006**                          
                                         AG (n=1)                             GG (n=22)                                                            CC (n=3)    TC (n=10)   TT (n=10)                            AG (n=2)    GG (n=21)
  mean                                   831.52                               175.4                                          mean                  5.56        1.625       1.188                        mean    3049.93     855.06
  stdev                                                                       95.28                                          stdev                 1.95        1.43        0.85                         stdev   1447.43     529.17
  -------------------------------------- ------------------------------------ ------------------------------------------- -- --------------------- ----------- ----------- ------------------------- -- ------- ----------- -----------
